Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
17
BLRX Quote, Financials, Valuation and Earnings
Last price:
$2.87
Seasonality move
:
-11.22%
Day range:
$2.86 - $3.10
52-week range:
$2.30 - $14.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.80x
P/B ratio:
0.65x
Volume:
62K
Avg. volume:
28.2K
1-year change:
-67.06%
Market cap:
$12.7M
Revenue:
$29.1M
EPS (TTM):
-$1.37
Analysts' Opinion
-
Consensus RatingBioLineRx Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $20.33, BioLineRx Ltd. has an estimated upside of 596.35% from its current price of $2.92.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $2.92.
Fair Value
-
According to the consensus of 2 analysts, BioLineRx Ltd. has 596.35% upside to fair value with a price target of $20.33 per share.
BLRX vs. S&P 500
-
Over the past 5 trading days, BioLineRx Ltd. has underperformed the S&P 500 by -3.58% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
BioLineRx Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioLineRx Ltd. revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter BioLineRx Ltd. reported revenues of $429K.
Earnings Growth
-
BioLineRx Ltd. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter BioLineRx Ltd. reported earnings per share of -$0.22.
Enterprise value:
-1.1M
EV / Invested capital:
-0.04x
Price / LTM sales:
0.80x
EV / EBIT:
-0.02x
EV / Revenue:
-0.09x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
0.08x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
-0.01x
Gross Profit (TTM):
$5.9M
Return On Assets:
-7.08%
Net Income Margin (TTM):
-24.06%
Return On Equity:
-18.74%
Return On Invested Capital:
-9.37%
Operating Margin:
-516.85%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $22M | $12.8M | $4.9M | $429K | |
| Gross Profit | -$865K | $14.5M | $5.9M | $3.7M | $225K | |
| Operating Income | -$39.5M | -$27.8M | -$10.4M | -$5.4M | -$2.2M | |
| EBITDA | -$38.7M | -$24.9M | -$8M | -$4.5M | -$2.1M | |
| Diluted EPS | -$0.85 | -$0.27 | -$1.37 | -$0.07 | -$0.22 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $62.8M | $57.9M | $28.8M | $37.8M | $28.5M | |
| Total Assets | $86.9M | $81.7M | $52.9M | $52.7M | $39.8M | |
| Current Liabilities | $10.3M | $8.1M | $14.7M | $25M | $13.7M | |
| Total Liabilities | $16M | $26.1M | $39.7M | $44.2M | $20.3M | |
| Total Equity | $70.9M | $55.5M | $13.1M | $8.5M | $19.5M | |
| Total Debt | $5.4M | $10.8M | $13.3M | $29.6M | $11.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$33.3M | -$30.3M | -$13.5M | -$9.8M | -$2.1M | |
| Cash From Investing | $25.7M | -$2.2M | $2.9M | $10.2M | $3.7M | |
| Cash From Financing | $2.7M | $33.5M | $9.1M | -$1.2M | -$930.3K | |
| Free Cash Flow | -$33.8M | -$30.3M | -$13.5M | -$9.8M | -$2.1M | |
BLRX
Sector
Market Cap
$12.7M
$27.9M
Price % of 52-Week High
19.87%
50.56%
Dividend Yield
0%
0%
Shareholder Yield
-127.75%
-1.55%
1-Year Price Total Return
-67.06%
-17.49%
Beta (5-Year)
1.290
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.95
200-day SMA
Sell
Level
$3.70
Bollinger Bands (100)
Sell
Level
3.27 - 3.91
Chaikin Money Flow
Sell
Level
-38.9M
20-day SMA
Sell
Level
$3.15
Relative Strength Index (RSI14)
Sell
Level
39.01
ADX Line
Sell
Level
25.41
Williams %R
Neutral
Level
-80
50-day SMA
Sell
Level
$3.36
MACD (12, 26)
Sell
Level
-0.14
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
48.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-14.4827)
Sell
CA Score
(Annual)
Level (-3.0564)
Sell
Beneish M-Score
(Annual)
Level (5.9819)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (6.2098)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.
Stock Forecast FAQ
In the current month, BLRX has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BLRX average analyst price target in the past 3 months is $20.33.
-
Where Will BioLineRx Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioLineRx Ltd. share price will rise to $20.33 per share over the next 12 months.
-
What Do Analysts Say About BioLineRx Ltd.?
Analysts are divided on their view about BioLineRx Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioLineRx Ltd. is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is BioLineRx Ltd.'s Price Target?
The price target for BioLineRx Ltd. over the next 1-year time period is forecast to be $20.33 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BLRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioLineRx Ltd. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BLRX?
You can purchase shares of BioLineRx Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioLineRx Ltd. shares.
-
What Is The BioLineRx Ltd. Share Price Today?
BioLineRx Ltd. was last trading at $2.87 per share. This represents the most recent stock quote for BioLineRx Ltd.. Yesterday, BioLineRx Ltd. closed at $2.92 per share.
-
How To Buy BioLineRx Ltd. Stock Online?
In order to purchase BioLineRx Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get BLRX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BLRX
Sector
P/E ratio
--
23.75x
PEG ratio
-0.01x
-0.01x
P/B ratio
0.65x
1.81x
Price / LTM sales
0.80x
1.59x
Growth Metrics
BLRX
Sector
Revenue growth
-91.32%
4.6%
Earnings growth
-206.74%
10.88%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.54
-$0.21
Profitability
BLRX
Sector
Profitability FY 2024
$19M
$3.6M
Return on invested capital
-9.37%
-31.84%
Return on assets
-7.08%
-27.96%
Return on equity
-18.74%
-37.63%
Earnings Date
Last Earnings Date
Nov
24
Next Earnings Date
Mar
31
Estimated Next Earnings Date
Feb
23
Balance Sheet
BLRX
Sector
Total cash
$25.2M
$26.3M
Short term investments
$9.1M
$25.7M
Total assets
$38.9M
$76.9M
Long term debt
$11.4M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
